0001193125-26-205021
SEC filingQ1 FY2026 net loss narrowed 31% to $7.6M as cost restructuring and lower R&D spend offset continued cash burn, with liquidity extended into H1 2028.
Operating income improved 36.8% to ($7.7M) for Q1 FY2026 compared to ($12.2M) in the prior year quarter. The improvement was primarily driven by lower personnel-related and consultant costs resulting from the corporate restructuring in February 2025, which reduced headcount. Additionally, product candidates in later stages of clinical development generally have higher development costs, and the company's pipeline prioritization contributed to lower research and development expenses.
Net cash used in operating activities decreased to ($6.3M) from ($12.5M) in the prior year quarter, reflecting the benefits of the restructuring and lower operating costs. The company continues to manage its liquidity carefully, with management noting that since inception, significant operating losses and negative cash flows from operations have been incurred. Management's projections of operating capital requirements are based on current operating plans, which include assumptions that may prove incorrect, and additional capital may be needed.
The company's lead product candidate, bempikibart, is advancing with Phase 2a Part B topline data expected in mid-2026. The program has received Fast Track designation from the FDA. The company continues to focus on its pipeline while managing costs through restructuring.
General and administrative expenses are expected to increase as the company continues to operate as a public company. To complete development of product candidates and build commercial infrastructure, substantial additional capital will be required. Management's outlook is based on present plans and business conditions, and actual results may differ materially.